Divi's Laboratories vs Lupin Q3 FY26

Divis Laboratories reported Q3 FY26 consolidated total income of INR 2,692 crore, up 12% YoY, driven by strong custom synthesis (57% mix) and stable generics volume. PAT stood at INR 583 crore, flat YoY due to a one-time exceptional item of INR 74 crore from labour code changes. Gross margins improved sharply to 63.7% (material consumption 36.3% of sales vs 39.8% last year) on favourable product mix. Management highlighted three dedicated CS projects progressing towards commercialization by Q3-Q4 CY2027, with validations ongoing. Peptide capabilities advanced with a dedicated commercial building for SPPS. Nutraceuticals contributed INR 214 crore in the quarter. Risks include continued generic pricing pressure and potential input cost impact from China's export tax rebate withdrawal. Overall, the company is well-positioned for double-digit growth with a strong pipeline and capacity expansion.

Guidance read

Three dedicated CS projects to commercialize by Q3-Q4 CY2027: Three custom synthesis molecules currently in validation/regulatory approval stages are expected to start commercial volumes in the second half of calendar year 2027. Double-digit revenue growth trajectory maintained: Management reiterated expectation of double-digit constant currency growth, supported by a balanced pipeline across patent phases. Phase two expansion at Kakinada under evaluation: Company is evaluating a second phase expansion at Unit 3 with 4 additional production blocks, but no final decision or timeline announced.

Risk read

Key risks include Generic pricing pressure persists — Pricing environment for generics remains competitive, limiting value growth despite volume increases.; China export tax rebate withdrawal may increase input costs — China's removal of export tax rebates on certain chemicals could lead to selective pricing pressures on raw materials, though company has diversified 78% of procurement domestically.; Regulatory approval delays for CS projects — Commercialization of three dedicated CS projects depends on customer regulatory approvals, which could face delays beyond the guided Q3-Q4 CY2027 timeline.; Concentration risk in peptide segment — Peptide capacity is largely dedicated to a single customer's requirements, creating dependency; management declined to disclose details on diversification..

Promise ledger

Of 2 tracked promises, management 0 met, 0 close, 2 missed.

LU

Lupin

Q3 FY26 · Diversified

Lupin delivered a strong Q3 FY26 with revenue of ₹7,168 crore (+24% YoY) and EBITDA margin of 31.1% (+681 bps YoY), driven by broad-based growth across regions. US sales hit a record $350 million (+46% YoY), supported by Tolvaptan exclusivity and Mirabegron settlement. India prescription business grew 10.9% YoY, with chronic share rising to 67%. Management raised FY26 EBITDA margin guidance to 27-28% (from 25-26%) and expects FY27 margins of 24-25% due to R&D investments and product mix. Key growth drivers include biosimilars (Pegfilgrastim launch imminent), injectables pipeline, and semaglutide launch in India. Risk: Mirabegron settlement costs and potential generic competition could pressure US profitability.

Guidance read

FY26 EBITDA margin guidance raised to 27-28%: Management raised full-year EBITDA margin guidance to 27-28% from earlier 25-26%, citing strong operational performance. FY27 EBITDA margin expected at 24-25%: For FY27, management guided EBITDA margin of 24-25%, factoring in higher R&D spend and potential product mix changes. R&D spend to remain 7.5-8.5% of sales: R&D expenditure is expected to stay in the 7.5-8.5% range going forward, with focus on complex generics and biosimilars. Semaglutide launch in India with first-year revenue target: Management expects semaglutide to be a ₹1,500 crore market opportunity in year one, with Lupin targeting ₹50-60 crore in first-year sales.

Risk read

Key risks include Mirabegron settlement costs and competition — The $90 million settlement (with $75 million amortized) will impact profitability, and potential generic entrants could erode market share.; US base business price erosion — Low single-digit price erosion in the US base business persists, which could offset volume gains if new product launches slow.; Biosimilar market competition — Increasing competition in biosimilars, including PBM private labels, could pressure margins despite Lupin's cost advantage.; Elixa development delays — The respiratory product Elixa has faced development delays; management expects material progress only in calendar 2026..

Promise ledger

Scorecard data is being built as historical quarters are processed.